Saturday, October 31, 2026

CrossAmerica Partners LP And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

November 21, 2021

CrossAmerica Partners LP  And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

(VIANEWS) - CrossAmerica Partners LP (CAPL), Eagle Materials (EXP), Conformis (CFMS) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. CrossAmerica Partners LP (CAPL)

20.4% sales growth and 32.51% return on equity

CrossAmerica Partners LP engages in the wholesale distribution of motor fuels, and ownership and leasing of real estate used in the retail distribution of motor fuels in the United States.

CrossAmerica Partners LP's sales growth this year is expected to be 51.3% and a negative 8% for next year.

Year-on-year quarterly revenue growth grew by 121.9%, now sitting on 2.47B for the twelve trailing months.

Volume

Today's last reported volume for CrossAmerica Partners LP is 21189 which is 54.16% below its average volume of 46228.

CrossAmerica Partners LP's sales growth for the next quarter is 20.4%. The company's growth estimates for the ongoing quarter and the next is a negative 64.3% and negative -50%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 32.51%.

Volatility

CrossAmerica Partners LP's last day, last week, and last month's current intraday variation average was 1.10%, 1.89%, and 1.99%, respectively.

CrossAmerica Partners LP's highest amplitude of average volatility was 2.65% (day), 4.45% (last week), and 3.22% (last month), respectively.

CrossAmerica Partners LP's Stock Yearly Top and Bottom Value

CrossAmerica Partners LP's stock is valued at $20.21 at 10:22 EST, way under its 52-week high of $23.24 and way above its 52-week low of $16.06.

CrossAmerica Partners LP's Moving Average

CrossAmerica Partners LP's value is under its 50-day moving average of $20.94 and above its 200-day moving average of $19.72.

2. Eagle Materials (EXP)

15.7% sales growth and 27.85% return on equity

Eagle Materials Inc., through its subsidiaries, produces and supplies heavy construction materials, light building materials, and materials used for oil and natural gas extraction in the United States.

Eagle Materials's sales growth this year is expected to be 13.7% and 8.5% for next year.

Year-on-year quarterly revenue growth grew by 13.9%, now sitting on 1.73B for the twelve trailing months.

Volume

Today's last reported volume for Eagle Materials is 446039 which is 27.67% above its average volume of 349342.

Eagle Materials's sales growth is a negative 0% for the current quarter and 15.7% for the next. The company's growth estimates for the ongoing quarter and the next is 27.3% and 10.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 27.85%.

Volatility

Eagle Materials's last day, last week, and last month's current intraday variation average was 2.59%, 2.06%, and 2.13%, respectively.

Eagle Materials's highest amplitude of average volatility was 2.71% (day), 2.81% (last week), and 2.97% (last month), respectively.

Eagle Materials's Stock Yearly Top and Bottom Value

Eagle Materials's stock is valued at $161.96 at 10:22 EST, under its 52-week high of $165.69 and way higher than its 52-week low of $87.96.

Eagle Materials's Moving Average

Eagle Materials's value is way higher than its 50-day moving average of $144.41 and way above its 200-day moving average of $144.53.

3. Conformis (CFMS)

14.2% sales growth and 10.4% return on equity

Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants.

Conformis's sales growth this year is expected to be 46.3% and a negative 31.2% for next year.

Year-on-year quarterly revenue growth declined by 11.6%, now sitting on 101.13M for the twelve trailing months.

Volume

Today's last reported volume for Conformis is 1864620 which is 22.46% below its average volume of 2405020.

Conformis's sales growth for the next quarter is 14.2%. The company's growth estimates for the current quarter and the next is 12.5% and 33.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.4%.

Volatility

Conformis's last day, last week, and last month's current intraday variation average was 5.78%, 3.90%, and 2.35%, respectively.

Conformis's highest amplitude of average volatility was 10.87% (day), 9.63% (last week), and 6.55% (last month), respectively.

Conformis's Stock Yearly Top and Bottom Value

Conformis's stock is valued at $0.99 at 10:22 EST, way below its 52-week high of $1.96 and way higher than its 52-week low of $0.60.

Conformis's Moving Average

Conformis's worth is way below its 50-day moving average of $1.30 and way below its 200-day moving average of $1.17.

4. A.O. Smith Corporation (AOS)

12.7% sales growth and 22.56% return on equity

A. O. Smith Corporation manufactures and markets residential and commercial gas and electric water heaters, boilers, tanks, and water treatment products in North America, China, Europe, and India.

A.O. Smith Corporation's sales growth this year is anticipated to be 18.3% and 8.5% for next year.

Year-on-year quarterly revenue growth grew by 20.7%, now sitting on 3.03B for the twelve trailing months.

Volume

Today's last reported volume for A.O. Smith Corporation is 891616 which is 15.25% below its average volume of 1052090.

A.O. Smith Corporation's sales growth for the next quarter is 12.7%. The company's growth estimates for the current quarter and the next is 4.5% and 2.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.56%.

Volatility

A.O. Smith Corporation's last day, last week, and last month's current intraday variation average was 3.04%, 1.29%, and 1.67%, respectively.

A.O. Smith Corporation's highest amplitude of average volatility was 3.10% (day), 1.94% (last week), and 2.62% (last month), respectively.

A.O. Smith Corporation's Stock Yearly Top and Bottom Value

A.O. Smith Corporation's stock is valued at $82.09 at 10:22 EST, below its 52-week high of $82.25 and way higher than its 52-week low of $52.08.

A.O. Smith Corporation's Moving Average

A.O. Smith Corporation's worth is way above its 50-day moving average of $68.82 and way above its 200-day moving average of $69.68.

5. TrueBlue (TBI)

12.2% sales growth and 9.02% return on equity

TrueBlue's sales growth this year is expected to be 15.2% and 8% for next year.

Year-on-year quarterly revenue growth grew by 43.7%, now sitting on 1.97B for the twelve trailing months.

Volume

Today's last reported volume for TrueBlue is 216629 which is 18.52% above its average volume of 182768.

TrueBlue's sales growth for the next quarter is 12.2%. The company's growth estimates for the current quarter and the next is 145.8% and 21.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.02%.

Volatility

TrueBlue's last day, last week, and last month's current intraday variation average was 1.78%, 1.77%, and 2.28%, respectively.

TrueBlue's highest amplitude of average volatility was 3.08% (day), 2.89% (last week), and 3.57% (last month), respectively.

TrueBlue's Stock Yearly Top and Bottom Value

TrueBlue's stock is valued at $26.05 at 10:22 EST, way below its 52-week high of $32.91 and way above its 52-week low of $16.66.

TrueBlue's Moving Average

TrueBlue's value is way under its 50-day moving average of $29.35 and under its 200-day moving average of $27.77.

6. Alamo Group (ALG)

11.2% sales growth and 10.66% return on equity

Alamo Group Inc. designs, manufactures, distributes, and services agricultural and infrastructure maintenance equipment for governmental and industrial use worldwide.

Alamo Group's sales growth this year is expected to be 13.8% and 7.3% for next year.

Year-on-year quarterly revenue growth grew by 16%, now sitting on 1.29B for the twelve trailing months.

Volume

Today's last reported volume for Alamo Group is 22982 which is 12.57% below its average volume of 26287.

Alamo Group's sales growth for the next quarter is 11.2%. The company's growth estimates for the ongoing quarter and the next is 83.9% and 17%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.66%.

Volatility

Alamo Group's last day, last week, and last month's current intraday variation average was 0.27%, 0.41%, and 0.98%, respectively.

Alamo Group's highest amplitude of average volatility was 1.33% (day), 2.36% (last week), and 2.23% (last month), respectively.

Alamo Group's Stock Yearly Top and Bottom Value

Alamo Group's stock is valued at $156.49 at 10:22 EST, under its 52-week high of $165.98 and way above its 52-week low of $131.17.

Alamo Group's Moving Average

Alamo Group's value is higher than its 50-day moving average of $148.44 and above its 200-day moving average of $149.79.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com